Dutch Stem Cell Biotech Neuroplast Secures € 10 Million (Us$ 11.5 Million) In Series B Funding To Further Advance Its Transformative Stem Cell Therapy For Traumatic Spinal Cord Injury
Dutch Stem Cell Biotech Neuroplast Secures € 10 Million (Us$ 11.5 Million) In Series B Funding To Further Advance Its Transformative Stem Cell Therapy For Traumatic Spinal Cord Injury
11/17/21, 7:06 AM
Location
geleenMoney raised
€10 million
Round Type
series b
Dutch clinical phase biotech Neuroplast raised a total of € 10 million (US$ 11.5 million) in funding from investors Lumana Invest, Brightlands Venture Partners, LIOF, and from the Innovation Credit from the Netherlands Enterprise Agency, to further advance the clinical development of a transformative treatment for Traumatic Spinal Cord Injury (TSCI). Neuroplast will use this Series B funding to obtain conditional EMA market approval for its Neuro-Cells® stem cell therapy.
Company Info
Location
geleen, limburg, netherlands
Additional Info
Neuroplast is a Dutch stem cell technology company focusing on fast-track development programs using autologous cell products for treatment of primarily inflammation-driven neurological disorders, with the aim of giving back perspective to people who suffer from those conditions.
The company was founded in August 2014 by physician Johannes de Munter and neurologist Erik Wolters. Current investors are Lumana Invest, Brightlands Venture Partners, LIOF and the Netherlands Enterprise Agency. Neuroplast is located in Brightlands Chemelot Campus in The Netherlands.